Introduction {#s1}
============

Breast cancer is the most frequently diagnosed tumor in women ([@bib56]). The etiology of breast cancer has been studied in detail, but the causes of breast cancer remain incompletely understood. Nevertheless, it is established that familial breast cancers result from germ-line mutations that increase the risk of cancer development ([@bib1]). Examples of inherited mutations that can cause breast cancer predisposition include *ATM*, *BRCA1/2*, *CDH1*, *CHEK2*, *NBN*, and *TP53*. Moreover, sporadic mutation of these and other genes promote the development of non-familial breast cancer ([@bib27]). Changes in the tumor genome are therefore important for breast cancer development ([@bib27]).

Recent advances in breast cancer genome analysis have led to significant progress towards the identification of sporadic mutations in breast cancer ([@bib7]; [@bib14]; [@bib18]; [@bib30]; [@bib44]; [@bib55]; [@bib58]; [@bib71]). These genetic changes include 'driver' mutations that promote tumor development and 'passenger' mutations that do not functionally contribute to the tumor phenotype. Genes mutated in familial cancer syndromes constitute a prime example of 'driver' mutations that can contribute to cancer development. The presence of 'passenger' mutations complicates the analysis of cancer genomes for the development of targeted tumor therapy. For example, some 'driver' mutations cause genetic instability (e.g. *ATM*, *BRCA1/2*, *CHEK2*, *NBN* and *TP53*) that can result in the accumulation of additional mutations in developing tumors.

Computational methods have been employed to distinguish 'driver' and 'passenger' mutations based on mutation frequency ([@bib46]), gene function in pathways ([@bib38]; [@bib73]), level of gene expression ([@bib4]) and predictions based on gene function ([@bib9]; [@bib29]; [@bib78]) and protein interactions ([@bib2]; [@bib12]). These computational approaches to identify 'driver' mutations have been complemented by functional siRNA screens on breast tumor cell lines ([@bib40]; [@bib51]). Collectively, these approaches have led to the identification of 'driver' mutations in human cancer, but it is likely that many more 'driver' mutations remain to be discovered ([@bib19]).

Examples of 'driver' mutations in breast cancer include the *TP53*, *PIK3CA*, and *PTEN* genes. Mutational inactivation of *PTEN* or activation of *PI3K* increases AKT/mTOR signaling that promotes growth, proliferation, and survival ([@bib79]), while mutation of *TP53* promotes cell survival and proliferation ([@bib68]). The appreciation of the importance of these pathways in cancer has spurred research into potential therapies ([@bib68]; [@bib79]). These well-established 'driver' mutations contribute to the etiology of breast cancer. In contrast, the role of some other highly mutated genes in breast cancer is unclear.

One frequently mutated pathway in breast cancer is the cJUN NH~2~-terminal kinase (JNK) pathway ([@bib19]). The JNK pathway is a three-tiered cascade that includes a MAP kinase kinase kinase (MAP3K) that phosphorylates and activates MAP kinase kinases (MAP2K) that, in turn, phosphorylate and activate JNK ([@bib16]). This pathway requires two MAP2K isoforms that co-operate to activate JNK by phosphorylation on tyrosine (by MAP2K4) and threonine (by MAP2K7) ([@bib62]). The sequencing of breast tumor genomic DNA has revealed mutations in genes that encode members of this pathway, including *MAP3K1*, *MAP2K4*, and *MAP2K7* ([@bib3]; [@bib7]; [@bib14]; [@bib18]; [@bib30]; [@bib44]; [@bib55]; [@bib58]; [@bib71]). The genetic changes include frequent deletion of the gene locus and mutations that cause protein truncation and loss of protein kinase activity. This analysis suggests that breast cancer is associated with loss of JNK signaling. Indeed, since AKT phosphorylates and inactivates MAP2K4 ([@bib45]), breast cancer 'driver' mutations that activate AKT (e.g. *PTEN* and *PI3K*) also cause loss of JNK signaling. The JNK signaling pathway may therefore be suppressed in many breast cancers.

The association of breast cancer with reduced JNK signaling represents a correlation. What is the significance of *loss-of-function* JNK pathway mutations? Are these 'driver' or 'passenger' mutations? The purpose of this study was to test the role of JNK signaling in breast cancer development. Since JNK signaling causes AP1 transcription factor activation, we anticipated that JNK may act to promote tumor growth. In contrast, we found that loss of JNK signaling in mammary epithelial cells caused breast cancer. Furthermore, JNK deficiency accelerated tumor formation in a murine model of breast cancer. These effects of JNK deficiency to promote tumor development were associated with widespread presence of early neoplasia and genomic instability. We show that JNK plays a key role in the initiation of tumor development. Thus, the frequent *loss-of-function* JNK pathway mutations in breast tumors represent 'driver' mutations that promote breast cancer development.

Results {#s2}
=======

Disruption of JNK signaling causes breast cancer development {#s2-1}
------------------------------------------------------------

*Loss-of-function* mutations in the JNK signaling pathway (e.g. *MAP3K1*, *MAP2K4*, and *MAP2K7*) are implicated in the etiology of breast cancer ([@bib3]; [@bib7]; [@bib14]; [@bib18]; [@bib30]; [@bib44]; [@bib55]; [@bib58]; [@bib71]). These potential 'driver' mutations in breast cancer cause disruption of JNK signaling. To test whether JNK pathway disruption influences breast cancer development, we examined the effect of JNK-deficiency in the mammary epithelium. The JNK1 (encoded by *Mapk8*) and JNK2 (encoded by *Mapk9*) isoforms exhibit partially redundant functions ([@bib16]). We therefore examined compound JNK deficiency in the mammary epithelium using Control (ME^CRE^: *Wap-Cre^+/- ^Mapk8^+/+ ^Mapk9^+/+^* and ME^WT^: *Mapk8^LoxP/LoxP^ Mapk9^LoxP/LoxP^*) mice and JNK-deficient (ME^KO^: *Wap-Cre^+/- ^Mapk8^LoxP/LoxP^ Mapk9^LoxP/LoxP^*) mice. Lactation induces *Wap-Cre* expression ([@bib69]). Studies using *Rosa26^mTmG+/-^* female reporter mice demonstrated *Cre*-mediated recombination in cytokeratin 8 (CK8) positive luminal epithelial cells ([Figure 1A](#fig1){ref-type="fig"}), but not in cytokeratin 5 (CK5) positive myoepithelial cells ([Figure 1B](#fig1){ref-type="fig"}).

![JNK deficiency in mammary epithelial cells causes genomic instability and tumor formation.\
(**A, B**) Mammary gland tissue sections were prepared from parous *Wap-Cre^+/- ^Rosa26^mTmG+/-^* female mice (n = 6) on day 21 post-weaning. These sections were stained with antibodies to cytokeratin 8 (CK8, red (**A**)) or cytokeratin 5 (CK5, red (**B**)), and GFP (green), and counterstained with DAPI (blue). Representative images are presented (*upper panel*, scale bar = 48 µm). Boxed area was magnified (*lower panel*, scale bar = 24 µm). (**C**) Summary of the study cohort showing the total number of *Mapk8^LoxP/LoxP^ Mapk9^LoxP/LoxP^* (ME^WT^) and *Wap-Cre^+/- ^Mapk8^LoxP/LoxP^ Mapk9^LoxP/LoxP^* (ME^KO^) mice examined, the number of mice exhibiting mammary intraepithelial neoplasia (MIN) or tumors (\*p=0.037, \*\*p=0.0084; Fisher's Exact Test) (*left panel*). The type of carcinoma is presented (*right panel*). (**D**) Extracts prepared from ME^KO^ and *Wap-Cre^+/- ^Trp53^LoxP/LoxP^* (JNK^WT^) tumor cells were subjected to immunoblot analysis using antibodies to JNK and α-Tubulin. The ME^KO^ tumors examined were representative of adenocarcinoma (\#1), tumors with characteristics of both adenocarcinoma and adenosquamous carcinoma (\#2), and adenosquamous carcinoma (\#3). (**E, F**) Representative hematoxylin and eosin (H and E) -stained sections of adenosquamous carcinomas (**E**) and adenocarcinomas (**F**) from ME^KO^ female mice are presented. Scale bar = 100 µm. (**G**) Exome sequencing was performed on ME^KO^ tumor cell lines (n = 3). Mammary tissue from a virgin female of the same genotype (*Wap-Cre^+/- ^Mapk8^LoxP/LoxP^ Mapk9^LoxP/LoxP^*) was used as the reference genome. Circos plots showing copy number variations (CNVs) in ME^KO^ tumor cells are presented. The outermost ring shows chromosome ideograms. The next track indicates high (red) and moderate (yellow) impact single nucleotide variants and indels marked by rectangles and triangles, respectively. The innermost track shows chromosome amplifications and deletions, with red and blue lines indicating chromosomal fragments present at log~2~(ratio tumor/normal)\>0.2 or log~2~(ratio tumor/normal)\<−0.2, respectively.\
10.7554/eLife.36389.006Figure 1---source data 1.Spreadsheet of source data for [Figure 1C](#fig1){ref-type="fig"}.\
10.7554/eLife.36389.007Figure 1---source data 2.Source image data for [Figure 1D](#fig1){ref-type="fig"}.Whole immunoblot scans are presented and the region used to construct [Figure 1D](#fig1){ref-type="fig"} is outlined.](elife-36389-fig1){#fig1}

We examined female control (ME^WT^ and ME^CRE^) mice and JNK-deficient (ME^KO^) mice to determine whether JNK deficiency causes breast tumor development. We found no breast cancer or pre-malignant mammary lesions in a cohort of 22 control ME^CRE^ mice ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). However, studies of a cohort of 19 control ME^WT^ mice identified one palpable breast tumor (adenosquamous carcinoma) in a 78 wk old mouse ([Figure 1C](#fig1){ref-type="fig"}). In addition, mammary intraepithelial neoplasia (MIN) was detected in one ME^WT^ mouse during microscopic analysis of tissue sections following necropsy. In contrast, the incidence of palpable breast tumors (31% of mice, median age 80 wk; p=0.037; Fisher's Exact Test) and MIN lesions detected at necropsy (41% of mice; p=0.0084; Fisher's Exact Test) in a cohort of 32 ME^KO^ mice was significantly greater than ME^WT^ mice ([Figure 1C](#fig1){ref-type="fig"}). Immunoblot analysis confirmed that the ME^KO^ adenocarcinoma and adenosquamous carcinoma cells do not express JNK proteins ([Figure 1D](#fig1){ref-type="fig"}). These data indicate that JNK deficiency promotes breast tumor development.

Microscopic analysis of tumor sections demonstrated the presence of adenosquamous carcinoma in ME^WT^ mice, but both adenocarcinoma and adenosquamous carcinoma were detected in ME^KO^ mice ([Figure 1C,E,F](#fig1){ref-type="fig"}). The adenocarcinomas were primarily CK8 positive and variably expressed estrogen receptor (ER) and progesterone receptor (PR), while the adenosquamous carcinomas expressed CK5 and did not express ER ([Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}). CK8 expression by ME^KO^ adenocarcinomas is consistent with both a luminal epithelial cell origin and the expression of *Wap-Cre* in luminal epithelial cells ([Figure 1A,B](#fig1){ref-type="fig"}). In contrast, CK5 expression by the ME^KO^ adenosquamous carcinomas suggests that these tumor cells may partially differentiate to express a marker of myoepithelial cells.

JNK deficiency promotes genomic instability and altered gene expression {#s2-2}
-----------------------------------------------------------------------

The JNK pathway has been implicated in genome maintenance ([@bib6]; [@bib39]; [@bib66]). To test whether JNK deficiency caused defects in genome stability, we examined the exome sequences of three independent ME^KO^ breast tumor cell lines ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). This analysis demonstrated single nucleotide variants (SNVs) and short insertions/deletions (Indels) ([Figure 1G](#fig1){ref-type="fig"}), including high impact SNVs and Indels (frame-shifts and stop codons) within gene coding regions ([Figure 1---figure supplement 2B,C](#fig1s2){ref-type="fig"}). Moreover, many chromosome segment amplifications and deletions (copy number variations, CNVs) were detected ([Figure 1G](#fig1){ref-type="fig"}). These data demonstrate that genomic instability is a consequence of JNK deficiency.

We compared gene expression profiles of three independent ME^KO^ tumor-derived cell lines and three independent primary *Wap-Cre^+/-^* epithelial cell (MEC) preparations. RNA-seq analysis identified 2217 differentially expressed genes (q \< 0.05, \|log~2~ Fold Change\| \> 0.75) that formed two clusters ([Figure 2A](#fig2){ref-type="fig"}). Pathway over-representation analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database revealed that both clusters were highly enriched for 'Pathways in Cancer' ([Figure 2B](#fig2){ref-type="fig"}). Cluster one was also enriched for 'Focal Adhesion', while Cluster two was enriched for 'Metabolic Pathways' and 'p53 Signaling' ([Figure 2B](#fig2){ref-type="fig"}). As expected, JNK deficiency caused reduced expression of AP1 transcription factors ([@bib67]) ([Figure 2C](#fig2){ref-type="fig"}). We also observed reduced expression of a 'DNA repair' gene signature ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) in ME^KO^ tumor cells compared with primary mammary epithelial cells (MEC), consistent with the detection of accumulated mutations in ME^KO^ tumor cells ([Figure 1G](#fig1){ref-type="fig"}).

![JNK deficiency promotes tumor-associated gene expression.\
(**A--D**) RNA-seq analysis was performed using primary mammary epithelial cells (MEC, n = 3) and ME^KO^ tumor cell lines (n = 3). K-means clustering was performed on differentially expressed genes and is presented as a heatmap (**A**). Pathway over-representation analysis using the KEGG database was performed on genes from each of the clusters. The pathways with the 10 lowest p~adj~ values are presented (**B**). The mean expression *Jun*, *Junb*, *Jund*, *Fos*, and *Fosb* mRNA is presented as a heatmap (**C**). Ingenuity Pathway Analysis of the RNA-seq data was used to predict signaling pathway activity (**D**). (**E**)** ***Wnt7b* and *Wnt10a* expression in MEC (n = 3) and ME^KO^ tumor cells (n = 3) is presented as the mean fragments per kilobase of exon model per million mapped fragments (FPKM) ± SEM. (**F**) WNT target gene expression (*Axin2*, *Ccnd1*, and *Myc*) in MEC (n = 3) and ME^KO^ (n = 3) cells is presented as the mean FPKM ± SEM.\
10.7554/eLife.36389.010Figure 2---source data 1.Spreadsheet of source data for [Figure 2](#fig2){ref-type="fig"}.](elife-36389-fig2){#fig2}

Ingenuity Pathway Analysis (IPA) identified a significant increase in 'WNT/β-Catenin Pathway' activity in ME^KO^ tumor cells compared with MEC ([Figure 2D](#fig2){ref-type="fig"}). Moreover, an enrichment of WNT signaling genes was found in the pathway over-representation analysis ([Figure 2B](#fig2){ref-type="fig"}, Cluster 2), including increased expression of *Wnt7b* and *Wnt10a* ([Figure 2E](#fig2){ref-type="fig"}) and increased expression of the WNT target genes *Axin2*, *Ccnd1*, and *Myc* in ME^KO^ cells compared with MEC ([Figure 2F](#fig2){ref-type="fig"}). These data suggest that ME^KO^ tumors may exploit the WNT pathway during tumor development.

JNK deficiency rapidly accelerates tumor development in a mouse model of breast cancer {#s2-3}
--------------------------------------------------------------------------------------

The observation that JNK deficiency promotes breast tumorigenesis ([Figure 1](#fig1){ref-type="fig"}) suggests that defects in JNK signaling may accelerate tumor development in a sensitized genetic background. To test this hypothesis, we examined the genetic interaction between JNK inactivation and loss of TRP53. Since *TP53* is the most frequently mutated gene in human breast cancer, this model is relevant to human disease ([@bib44]).

We established TRP53-deficient mice (JNK^WT^: *Wap-Cre^+/- ^Trp53*^LoxP/LoxP^) and TRP53/JNK compound mutant mice (JNK^KO^: *Wap-Cre^+/- ^Trp53^LoxP/LoxP^ Mapk8^LoxP/LoxP^ Mapk9^LoxP/LoxP^*). Loss of JNK on the TRP53-deficient background dramatically accelerated tumor formation ([Figure 3A](#fig3){ref-type="fig"}). Histological examination of the JNK^WT^ and JNK^KO^ tumors confirmed that the majority of lesions were adenocarcinomas ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). JNK^WT^ and JNK^KO^ tumors presented with variable ER and PR staining patterns ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Moreover, both JNK^WT^ and JNK^KO^ tumor cells primarily expressed the luminal marker CK8, consistent with a luminal epithelial cell origin, although some dispersed cells did express the myoepithelial cell marker CK5 ([Figure 3C](#fig3){ref-type="fig"}).

![JNK deficiency accelerates tumor formation in a mouse model of breast cancer.\
(**A**) Mammary tumor-free survival was monitored in cohorts of 26 *Wap-Cre^+/- ^Trp53*^*LoxP/LoxP*^ (JNK^WT^) mice and 32 *Wap-Cre^+/- ^Trp53^LoxP/LoxP^ Mapk8^LoxP/LoxP^ Mapk9^LoxP/LoxP^* (JNK^KO^) mice. Animals euthanized before a palpable mammary tumor had formed were censored in the log-rank analysis. (**B**) Tissue sections were prepared from JNK^WT^ mammary tumors (n = 11) and JNK^KO^ mammary tumors (n = 35). Representative images of H and E-stained sections from JNK^WT^ (*upper panel*) and JNK^KO^ (*lower panel*) mice are presented. Scale bar = 100 µm. (**C**) Adenocarcinoma tissue sections from JNK^WT^ mice (*upper panel*) and JNK^KO^ mice (*lower panel*) were stained with antibodies to (from left to right) estrogen receptor (ER), progesterone receptor (PR), cytokeratins 5 (red) and 8 (green) (CK5 and CK8 respectively), PCNA (Scale bars = 50 µm), and cleaved caspase 3 (Scale bar = 100 µm). Immunofluorescent stains were counterstained with DAPI, and peroxidase-based staining was counterstained with hematoxylin. Representative images are presented. (**D, E**) Exome sequencing was performed on JNK^WT^ (n = 2) and JNK^KO^ (n = 6) tumor cell lines. Mammary tissue from a virgin female of the same genotype (*Wap-Cre^+/- ^Trp53*^*LoxP/LoxP*^ for JNK^WT^ and *Wap-Cre^+/- ^Trp53^LoxP/LoxP^ Mapk8^LoxP/LoxP^ Mapk9^LoxP/LoxP^* for JNK^KO^) was used as the reference genome. Representative Circos plots showing CNVs are presented for JNK^WT^ (**D**) and JNK^KO^ (**E**) tumor cells. The outermost ring shows chromosome ideograms. The next track indicates high (red) and moderate (yellow) impact single nucleotide variants and indels marked by rectangles and triangles, respectively. The innermost track shows chromosome amplifications and deletions, with red and blue lines indicating chromosomal fragments present at log~2~(ratio tumor/normal)\>0.2 or log~2~(ratio tumor/normal)\<−0.2, respectively.\
10.7554/eLife.36389.015Figure 3---source data 1.Spreadsheet of source data for [Figure 3A](#fig3){ref-type="fig"}.](elife-36389-fig3){#fig3}

To test whether JNK deficiency promotes tumorigenesis by disrupting the balance of proliferation and cell death, we stained tumor tissue sections with antibodies to detect the proliferation marker PCNA and the apoptotic marker cleaved caspase 3. No differences were detected in PCNA-stained sections, indicating that JNK^KO^ tumors were not more proliferative than JNK^WT^ tumors ([Figure 3C](#fig3){ref-type="fig"}). Similarly, we did not detect differences in cleaved caspase 3 staining between JNK^WT^ and JNK^KO^ tumors ([Figure 3C](#fig3){ref-type="fig"}). Collectively, these data show that JNK deficiency causes significantly accelerated disease progression without greatly changing the tumor phenotype.

To assess whether there are differences in mutational load, and to determine if there are recurring mutations or chromosomal alterations associated with the different tumor genotypes, we performed exome sequencing of JNK^WT^ and JNK^KO^ tumor cell lines ([Figure 3D,E](#fig3){ref-type="fig"} and [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). High impact SNVs and Indels were identified ([Figure 1---figure supplement 2B,C](#fig1s2){ref-type="fig"}). CNV analysis demonstrated that chromosome six was amplified and no chromosome was consistently deleted in JNK^WT^ tumor cells ([Figure 3D](#fig3){ref-type="fig"}). Chromosome six was also amplified in some (two of six) JNK^KO^ tumor cells ([Figure 3E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). The proto-oncogene *Kras* resides on chromosome six and CNV analysis demonstrated that the *Kras* locus was recurrently amplified in JNK^WT^ tumor cells ([Figure 3D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}) and was more highly expressed ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). The reduced amplification of the *Kras* locus in JNK^KO^ tumor cells compared with JNK^WT^ tumor cells suggests that an alternative mechanism of *Kras* regulation may contribute to the phenotype of these tumor cells. Indeed, increased expression of a 'KRAS signaling' gene signature was detected in both JNK^WT^ and JNK^KO^ tumor cells ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}).

Effects of JNK deficiency on tumor-associated gene expression {#s2-4}
-------------------------------------------------------------

We performed RNA-seq on primary mammary epithelial cells (MEC) and tumor cells ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) to test whether JNK deficiency caused changes in tumor-associated gene expression. An examination of genes differentially expressed (\|log~2~ Fold Change\| \> 0.75; q \< 0.05) in tumor cells compared to MEC revealed distinct gene expression patterns between JNK^WT^, JNK^KO^, and ME^KO^ tumor cells ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Pathway over-representation analysis using the KEGG database ([Figure 4B](#fig4){ref-type="fig"}) demonstrated that up-regulated genes in JNK-deficient tumors were enriched for 'Metabolic Pathways' (Clusters 1 and 2), while genes up-regulated in JNK^WT^ tumors were enriched for 'Cytokine-Cytokine Receptor Interactions' (Cluster 3). In contrast, down-regulated genes in all of the tumor cells were enriched for 'Focal Adhesion Proteins' (Cluster 4). These data indicate that JNK deficiency selectively alters a subset of tumor-associated gene expression.

![RNA-seq analysis demonstrates that a sub-set of tumor-associated gene expression requires JNK.\
(**A, B**) RNA isolated from primary mammary epithelial cells (MEC, n = 3) and also JNK^WT^ (n = 2), ME^KO^ (n = 3), and JNK^KO^ (n = 2) tumor cell lines was sequenced. The heatmap presents k-means clustering (k = 4) of genes differentially expressed in any of the pairwise comparisons (q \< 0.05, \|log~2~ Fold Change\| \> 0.75; mean) (**A**). Pathway over-representation analysis was performed on each of the four clusters using the KEGG database (**B**). The pathways with the lowest *p~adj~* values for each cluster are presented. (**C**) Comparative analysis was performed on genes differentially expressed between MEC and the tumor cell lines using Ingenuity Pathway Analysis (IPA). Heatmaps show the predicted activation (Activation z-score) of canonical pathways involved in immune (*left panel*) and integrin/cytoskeleton (*right panel*) signaling (cutoff score = 1.31; equates to p=0.049 using Fisher's Exact Test).\
10.7554/eLife.36389.020Figure 4---source data 1.Spreadsheet of source data for [Figure 4](#fig4){ref-type="fig"}.](elife-36389-fig4){#fig4}

To understand how JNK deficiency may alter tumor-signaling pathways, we used IPA to predict pathway activation status by examining differential expression between each tumor type and MEC. The pathways were ranked by Activation z-Score (total -log~10~*p* of Fisher's Exact Test across the tumors) and the top 100 were considered ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Two dominant categories emerged from the comparative analysis: down-regulated 'Chemokine/Cytokine Signaling'; and down-regulated 'Integrin/Cytoskeleton Signaling' ([Figure 4C](#fig4){ref-type="fig"}).

We also examined signaling pathways by immunoblot analysis. Studies of JNK^WT^ tumor cells demonstrated the presence of a functional JNK signaling pathway, including stress-induced phosphorylation of both JNK and cJUN ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). However, JNK was not detected in JNK^KO^ tumor cells ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}). The activation state of other MAPK pathways (ERK and p38) and the AKT pathway were similar between JNK^WT^ and JNK^KO^ tumor cells ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}).

JNK deficiency does not increase tumor stem cell activity {#s2-5}
---------------------------------------------------------

The increased mammary tumor formation ([Figure 3A](#fig3){ref-type="fig"}) caused by JNK deficiency may reflect a role of JNK in tumor stem cells. To examine this potential role of JNK, we monitored mammosphere formation and maintenance using JNK^WT^ and JNK^KO^ tumor cells. No evidence of increased mammosphere propagation by the JNK^KO^ tumor cells was obtained ([Figure 5A,B](#fig5){ref-type="fig"}). Moreover, we did not detect enhanced sphere formation by ME^KO^ tumor cells ([Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}). Staining of agarose-embedded JNK^WT^ and JNK^KO^ mammospheres revealed a similar organization with peripheral CK5^+^ cells and central CK8^+^ cells ([Figure 5C](#fig5){ref-type="fig"}). Finally, the expression of stem cell markers (*Bmi1*, *Nanog*, and *Pou5f1*) was not significantly different between JNK^WT^ and JNK^KO^ mammospheres ([Figure 5D](#fig5){ref-type="fig"}). This analysis does not support the conclusion that differences in cancer stem cell activity account for the accelerated tumor formation by JNK^KO^ mice compared with JNK^WT^ mice.

![Stem cell populations are comparable in JNK^WT^ and JNK^KO^ tumor cells.\
(**A**) JNK^WT^ and JNK^KO^ tumor cells formed mammospheres when grown in suspension. Two independent cell lines were tested for each genotype. Representative phase contrast (*upper panel*) and H and E-stained agarose-embedded sphere sections (*lower panel*) are presented. Representative images are presented. Scale bar = 100 µm. (**B**) The number of mammospheres formed per 1000 plated cells each passage (P) was quantitated for JNK^WT^ and JNK^KO^ tumor cells. Two independent cell lines were tested for each genotype. The data presented are the mean ± SEM (n = 3 independent experiments). No significant differences were observed (p\>0.05). (**C**) Representative agarose-embedded mammosphere sections stained with antibodies to cytokeratin 5 (CK5, red) and cytokeratin 8 (CK8, green), and counterstained with DAPI are presented. Scale bar = 50 µm. (**D**) RNA was isolated from JNK^WT^ and JNK^KO^ tumor cell mammospheres at different passages to quantify mRNA expression of *Bmi1*, *Nanog*, and *Pou5f1*. Two independent cell lines were tested for each genotype. The data presented are the mean ± SEM (n = 2 independent experiments). No significant differences were observed (p\>0.05).\
10.7554/eLife.36389.026Figure 5---source data 1.Spreadsheet of source data for [Figure 5](#fig5){ref-type="fig"}.](elife-36389-fig5){#fig5}

JNK deficiency does not increase tumor cell proliferation, but does promote survival {#s2-6}
------------------------------------------------------------------------------------

Transformed cells co-opt cellular processes to block anti-proliferative and death mechanisms while increasing cell proliferation, invasion, and migration ([@bib27]). A change in one of these processes may account for the increased tumor formation detected in JNK^KO^ mice. No differences between JNK^WT^ and JNK^KO^ tumor cell proliferation were detected ([Figure 6A](#fig6){ref-type="fig"}). Similarly, we found no difference in JNK^WT^ and JNK^KO^ tumor cell migration during wound healing ([Figure 6B](#fig6){ref-type="fig"}) or in response to a serum gradient ([Figure 6C](#fig6){ref-type="fig"}). Moreover, JNK^WT^ and JNK^KO^ tumor cell invasion through matrigel-coated membranes ([Figure 6C](#fig6){ref-type="fig"}) and collagen I-filled wounds ([Figure 6D](#fig6){ref-type="fig"}) was similar. These data demonstrate that JNK deficiency does not alter breast tumor cell proliferation, invasion, or migration. Consistent with this conclusion, we found no differences between the growth of JNK^WT^ and JNK^KO^ tumor cells in orthotopically transplanted syngeneic mice ([Figure 6E--G](#fig6){ref-type="fig"}).

![JNK^WT^ and JNK^KO^ tumor cells exhibit similar phenotypes.\
(**A**) JNK^WT^ (n = 2) and JNK^KO^ (n = 6) tumor cell lines were cultured (8 hr) in growth media and the change in confluence was measured using an IncuCyte ZOOM (mean ± SEM). No significant differences (p\>0.05) were observed. Similar data were obtained in four independent experiments. (**B**) Monolayers of JNK^WT^ (n = 2) and JNK^KO^ (n = 4) cells were wounded and cell migration rates were assessed by measuring the change in wound width 48 hr after wounding using an IncuCyte ZOOM (mean ± SEM). No significant differences (p\>0.05) were observed. Similar data were obtained in two independent experiments. (**C**) JNK^WT^ (n = 2) and JNK^KO^ (n = 6) tumor cell chemotaxis in response to a serum gradient in the absence (Control) or presence of Matrigel was examined (mean ± SEM). No significant differences were observed (p\>0.05). Similar data were obtained in two independent experiments. (**D**) Monolayers of JNK^WT^ (n = 2) and JNK^KO^ (n = 3) tumor cells were wounded, overlayed with 0.5 mg/ml collagen I in growth serum, and cultured for up to 48 hr in media containing 2% serum. Tumor cell migration into the collagen-filled wound was quantitated by measuring cell density in the initial wound area using an IncuCyte ZOOM (mean ± SEM). No significant differences were observed (p\>0.05). Similar data were obtained in two independent experiments. (**E--G**) Orthotopic transplantation of JNK^WT^ and JNK^KO^ tumor cells (two independent cell lines per genotype) into the mammary fat pads of 26 (JNK^WT^) and 27 (JNK^KO^) syngeneic wild-type host mice was performed using 2 × 10^6^ tumor cells (**E**). Orthotopic transplantation of 0.5 × 10^6^ tumor cells was performed using 30 (JNK^WT^) and 26 (JNK^KO^) syngeneic wild-type host mice (**F**). No significant differences were observed (p\>0.05). Representative H and E-stained tumor sections from JNK^WT^ (*upper panel*) and JNK^KO^ (*lower panel*) tumors are presented (**G**). Scale bar = 100 µm. (**H, I**) JNK^WT^ (n = 2) and JNK^KO^ (n = 4) tumor cell lines were cultured in soft agar and colony formation was quantitated (mean ± SEM) (**H**). Similar data were obtained from two independent experiments and representative images of crystal violet-stained colonies are presented (**I**). Scale bar = 100 µm. (**J**) Two JNK^WT^ and five JNK^KO^ tumor cell lines were cultured in suspension (24 hr) and apoptotic cells (7AAD^-^ annexin V^+^) were quantitated by flow cytometry (mean ± SEM; n = 7 for JNK^WT^ and n = 16 for JNK^KO^).\
10.7554/eLife.36389.029Figure 6---source data 1.Spreadsheet of source data for [Figure 6](#fig6){ref-type="fig"}.](elife-36389-fig6){#fig6}

While many properties of JNK^WT^ and JNK^KO^ tumor cells are similar ([Figure 6A--G](#fig6){ref-type="fig"}), we did detect some JNK-dependent differences in the tumor cell phenotype ([Figure 6H--J](#fig6){ref-type="fig"}). Thus, JNK^KO^ tumor cells formed more colonies than JNK^WT^ tumor cells when grown in soft agar ([Figure 6H,I](#fig6){ref-type="fig"}) and JNK^KO^ cells exhibited greater resistance to anoikis than JNK^WT^ tumor cells ([Figure 6J](#fig6){ref-type="fig"}). These data indicate that JNK deficiency can promote tumor cell survival.

JNK deficiency causes early disease initiation {#s2-7}
----------------------------------------------

Comparative studies of JNK^WT^ and JNK^KO^ tumor cells demonstrated that JNK-deficiency does not contribute to differences in proliferation, migration, or invasion phenotypes in vitro ([Figure 6A--D](#fig6){ref-type="fig"}) or to tumor growth in orthotopically transplanted syngeneic mice ([Figure 6E--G](#fig6){ref-type="fig"}). We therefore considered the possibility that JNK may influence tumor initiation rather than the function of fully developed tumor cells. To test this hypothesis, we examined sections of mammary glands from female mice at 18 weeks after gene ablation. JNK^WT^ mice presented normal mammary gland morphology ([Figure 7A](#fig7){ref-type="fig"}). In contrast, multifocal mammary intraepithelial neoplasia (MIN) was observed in JNK^KO^ glands ([Figure 7A](#fig7){ref-type="fig"}). The presence of MIN lesions in young JNK^KO^ mice indicates that JNK-deficient mammary epithelial cells exhibit defects in apical-basal polarity, a hallmark of mammary tumor development ([@bib25]; [@bib81]). Moreover, it is likely that mammary tumor development is further promoted by the increased survival of JNK^KO^ cells in vitro ([Figure 6H--J](#fig6){ref-type="fig"}) and increased proliferation of JNK^KO^ epithelial cells compared with JNK^WT^ epithelial cells in vivo ([Figure 7B,C](#fig7){ref-type="fig"}). These data indicate that one physiological function of JNK in mammary epithelial cells is to suppress breast cancer development by preventing the initiation of carcinogenesis.

![JNK deficiency promotes early disease lesions.\
(**A**) Eighteen weeks after gene deletion, tissue sections were prepared from mammary glands of JNK^WT^ (n = 5) and JNK^KO^ (n = 12) female mice. The mice were not matched for estrus cycle. Representative H and E-stained sections are presented. Scale bar = 100 µm. (**B, C**) Proliferation was examined in mammary glands at 18 weeks after gene ablation by staining tissue sections with an antibody to PCNA (JNK^WT ^n = 4 mice, JNK^KO ^n = 5 mice). Representative PCNA-stained and DAPI counter-stained glands are presented (B, Scale bar = 50 µm). The percent of PCNA^+^ cells was quantified (mean ± SEM) (**C**).\
10.7554/eLife.36389.031Figure 7---source data 1.Spreadsheet of source data for [Figure 7](#fig7){ref-type="fig"}.](elife-36389-fig7){#fig7}

Discussion {#s3}
==========

The frequent mutation of the JNK pathway in human breast cancer (including the genes *MAP3K1*, *MAP2K4*, and *MAP2K7*) implicates reduced JNK signaling in the etiology of mammary carcinoma ([@bib3]; [@bib7]; [@bib14]; [@bib18]; [@bib30]; [@bib44]; [@bib55]; [@bib58]; [@bib71]). Mutation of *Mapk8* (encodes JNK1) and *Mapk9* (encodes JNK2) is not frequently detected, most likely because of the functional redundancy of these JNK isoforms ([@bib16]). In contrast, MAP2K4 and MAP2K7 serve as non-redundant activators of JNK and mutation of either *MAP2K4* or *MAP2K7* causes JNK inhibition ([@bib62]). Similarly, MAP3K1 can act in a non-redundant manner to activate JNK ([@bib80]). Tumor-associated ablation or mutation of these genes therefore causes JNK inhibition. Moreover, JNK signaling is also inhibited by phosphorylation of MAP2K4 by AKT ([@bib45]) in breast tumors with AKT activation caused by 'driver' mutations in *PTEN* or *PIK3CA* ([@bib19]). Suppression of JNK signaling is therefore a characteristic of many breast cancers. Nevertheless, the significance of JNK pathway inactivation in breast cancer is unclear ([@bib10]; [@bib11]). Here, we demonstrate that loss of JNK signaling promotes murine breast cancer development ([Figure 1](#fig1){ref-type="fig"}). Furthermore, JNK deficiency accelerated tumor development in a murine model of breast cancer ([Figure 3](#fig3){ref-type="fig"}). The frequent JNK pathway *loss-of-function* mutations in human breast cancer may therefore represent 'driver' mutations that promote tumor development.

We find that JNK loss plays a key role at the early stages of breast cancer development by promoting mammary gland neoplasia ([Figure 7](#fig7){ref-type="fig"}). This observation likely accounts for the effect of mutational inactivation of JNK signaling to promote tumor development ([Figure 1 and 3](#fig1){ref-type="fig"}). In contrast to this tumor-suppressive role of JNK during early stages of carcinogenesis ([Figure 7](#fig7){ref-type="fig"}), JNK does not markedly influence the late-stage tumor phenotype ([Figure 6](#fig6){ref-type="fig"}). Thus, JNK does not change tumor cell proliferation, invasion or migration in vitro or tumor formation in orthotopically transplanted mice in vivo ([Figure 6](#fig6){ref-type="fig"}). However, JNK deficiency does repress tumor cell anoikis and promotes growth in soft agar in vitro ([Figure 6](#fig6){ref-type="fig"}). JNK therefore plays a major role in early tumor development, but only a minor role in established tumors.

An important question relates to the mechanism of breast tumor suppression by the JNK signaling pathway. Part of the mechanism may reflect the pro-apoptotic role of JNK ([@bib63]). Mutations in key genes can enable epithelial cell survival in the luminal space, resulting in ductal carcinoma in situ (DCIS) and cancer ([@bib25]; [@bib35]; [@bib48]; [@bib60]). Indeed, JNK deficiency has been shown to impair efficient epithelial cell death in response to cell detachment (anoikis) in vitro and cause both occlusion of mammary ducts ([@bib10]; [@bib21]) and delayed involution ([@bib22]) in vivo. It is therefore possible that these types of cell survival responses in the mammary epithelium may contribute to tumor development. However, this mechanism may not be sufficient to account for the tumor formation caused by JNK deficiency ([Figure 1](#fig1){ref-type="fig"}) or the observed acceleration of tumor formation caused by JNK deficiency in a mouse model of breast cancer ([Figure 3](#fig3){ref-type="fig"}). For example, both JNK and p38 MAPK promote mammary gland epithelial cell anoikis by a BIM-dependent mechanism and are required for luminal clearance of mammary ducts ([@bib10]; [@bib21]; [@bib72]), but JNK inhibition promotes breast cancer ([Figure 1 and 3](#fig1){ref-type="fig"}) while p38 MAPK pathway inhibition suppresses breast cancer development and promotes the early dissemination of tumor cells ([@bib17]; [@bib20]; [@bib28]). These data indicate that anoikis defects and ductal occlusion by detached epithelial cells caused by stress-activated MAPK inhibition is not sufficient for tumor formation. This reasoning implicates a second pathway of JNK-mediated suppression of mammary tumor development.

Insight into JNK-mediated tumor suppression was obtained from the analysis of tumor genomic DNA. We found that JNK deficiency caused genomic instability associated with widespread SNVs, Indels, and CNVs ([Figure 1G](#fig1){ref-type="fig"}). It is likely that these genetic changes caused by JNK deficiency contribute to tumor development. This genetic instability reflects the function of JNK to promote genome maintenance in response to stress. Examples include JNK-mediated phosphorylation of SIRT6 to stimulate double-stranded DNA break repair ([@bib66]) and JNK-mediated phosphorylation of DGCR8 to induce transcription-coupled nucleotide excision repair ([@bib6]). Loss of JNK signaling would therefore be expected to cause defects in DNA repair that result in increased genomic instability. Indeed, our analysis demonstrates that JNK deficiency in the mammary epithelium causes genomic instability ([Figure 1G](#fig1){ref-type="fig"}) and breast cancer ([Figure 1C](#fig1){ref-type="fig"}). JNK deficiency may therefore increase the sensitivity of tumor cells to drugs that cause DNA damage. This represents a potential opportunity for the design of therapeutic strategies for the treatment of tumors with defects in JNK signaling.

The TRP53 pathway is known to be important for genome stability and tumor suppression. Our data demonstrate that the JNK pathway similarly promotes genome stability and tumor suppression. The number of SNVs and indels caused by TRP53 deficiency was greater than that caused by JNK deficiency. Nevertheless, the number of CNVs were similar on both genetic backgrounds. These observations indicate that while both TRP53-deficiency and JNK-deficiency can cause genomic instability, the mechanisms engaged by these two pathways may be different.

The identification of JNK pathway mutations as 'driver' mutations for breast cancer was not anticipated. For example, the JNK pathway can promote cell proliferation and survival through regulation of AP1 transcription factors ([@bib15]; [@bib33]; [@bib67]). Indeed, the JNK/JUN signaling pathway may promote the proliferation of some breast tumor cells in vitro ([@bib24]; [@bib76]). It is therefore possible that JNK signaling may have pro-oncogenic functions in certain tumor types or under specific conditions ([@bib74]). Nevertheless, our analysis establishes that a major role of JNK signaling in the breast epithelium is tumor suppression ([Figure 1 and 3](#fig1){ref-type="fig"}). This role of JNK signaling is consistent with the discovery of frequent JNK pathway gene ablation and mutation in human breast cancer ([@bib3]; [@bib7]; [@bib14]; [@bib18]; [@bib30]; [@bib44]; [@bib55]; [@bib58]; [@bib71]).

The major conclusions of this study are that: (1) JNK deficiency in the mammary epithelium can cause murine breast cancer; and (2) JNK deficiency rapidly accelerates tumor development in a mouse model of breast cancer. These observations indicate that JNK can act as a breast cancer tumor suppressor. This is a significant finding because frequent mutational inactivation of genes that encode JNK pathway components (e.g. *MAP2K4* and *MAP3K1*) are detected in human breast cancer ([@bib19]). However, it should be noted that the compound disruption of JNK expression that we have studied most likely differs from the loss of individual JNK pathway components (e.g. MAP2K4 and MAP3K1) because of partial compensation by alternative signaling molecules, including MAP2K7 and members of the MAP3K family. Whether reduced JNK activity caused by loss of MAP2K4 or MAP3K1 phenocopies the effects of compound JNK deficiency on breast cancer is unclear. An important goal for future studies will be to directly test the effect of *MAP2K4* and *MAP3K1* gene mutation on breast cancer.

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

We have previously described *Mapk8^LoxP/LoxP^ Mapk9^LoxP/LoxP^* mice ([@bib26]). C57BL6/J (RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)), B6129-TG(Wap-cre)11738Mam/J (RRID:[IMSR_JAX:008735](https://scicrunch.org/resolver/IMSR_JAX:008735)) ([@bib69]), B6.129P2-*Trp53^tm1Brn^*/J (RRID:[IMSR_JAX:008462](https://scicrunch.org/resolver/IMSR_JAX:008462)) ([@bib41]), and B6.129(Cg)-Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo^/J mice (RRID:[IMSR_JAX:007676](https://scicrunch.org/resolver/IMSR_JAX:007676)) ([@bib42]) were purchased from The Jackson Laboratories (Bar Harbor, ME). All mice were on a C57BL6/J strain background (10 generations back-crossed). Female mice were bred at 10--12 weeks of age and monitored for tumor development by palpation following weaning. Reasons for euthanasia included a tumor of 1 cm in diameter, ulceration due to the tumor, poor health, or weight loss (\>20% body weight). The animals were housed in a specific pathogen-free facility accredited by the American Association of Laboratory Animal Care (AALAC).

Tumor-derived cell lines {#s4-2}
------------------------

Tumors were harvested and placed in DMEM/F12 medium supplemented with 1% penicillin/streptomycin and 1% nystatin (Thermo Fisher Scientific, Waltham, MA). The tissue was washed with phosphate-buffered saline (PBS), minced, and digested (37°C for up to 2 hr, shaking) in DMEM supplemented with 2 mg/ml collagenase, 0.1% trypsin, and 1% penicillin/streptomycin. Following digestion, cells were pelleted and re-suspended in DMEM/F12 supplemented with 2% fetal bovine serum and 1% penicillin/streptomycin, then plated on collagen I (Thermo Fisher Scientific Cat\# A1048301) coated dishes. After two passages, the cells were plated on standard tissue culture dishes and maintained in Growth Medium (DMEM/F12 supplemented with 10% fetal bovine serum plus 1% penicillin/streptomycin) prior to cryogenic storage.

Genotype analysis {#s4-3}
-----------------

Genomic DNA was genotyped using a PCR-based method. *Mapk8^LoxP^* (540 bp) and *Mapk8^+^* (330 bp) were detected using amplimers 5'-AGGATTTATGCCCTCTGCTTGTC-3' and 5'-GACCACTGTTCCAATTTCCATCC-3'. *Mapk9^LoxP^* (264 bp) and *Mapk9^+^* (224 bp) were detected using amplimers 5'-GTTTTGTAAAGGGAGCCGAC-3' and 5'-CCTGACTACTGAGCCTGGTTTCTC-3'. *Trp53^LoxP^* (370 bp) and *Trp53^+^* (288 bp) were detected using amplimers 5'-AGCACATAGGAGGCAGAGAC-3' and 5'-CACAAAAACAGGTTAAACCCAG-3'. *Cre^+^* (450 bp) was detected using amplimers 5'-TTACTGACCGTACACCAAATTTGCCTGC-3' and 5'-CCTGGCAGCGATCGCTATTTTCCATGAGTG-3'. *Mapk8^Δ^* (395 bp), *Mapk8^+^* (1550 bp), and *Mapk8^LoxP^* (1,095 bp) were detected using amplimers 5'-CCTCAGGAAGAAAGGGCTTATTTC-3' and 5'-GAACCACTGTTCCAATTTCCATCC-3'. *Mapk9^Δ^* (400 bp) and *Mapk9^LoxP^* (560 bp) were detected using 5'-GGAATGTTTGGTCCTTTAG-3', 5'-GCTATTCAGAGTTAAGTG-3', and 5'-TTCATTCTAAGCTCAGACTC-3'. *Trp53^Δ^* (612 bp) was detected using amplimers 5'-GAAGACAGAAAAGGGGAGGG-3' and 5'-CACAAAAACAGGTTAAACCCAG-3'.

Orthotopic transplantation {#s4-4}
--------------------------

Tumor-derived cell lines were screened for common pathogens using the Rapidmap panel 21 (Taconic Biosciences, New York, NY). The cells were pelleted and washed five times with PBS before resuspension at a final concentration of 2 × 10^6^ or 0.5 × 10^6^ cells/40 µl of PBS. A 26-guage needle was used to inject the cells into the thoracic mammary gland. The presence of tumors was monitored weekly and palpable tumors were measured using calipers. Mice meeting euthanasia criteria or mice that remained 80 days post-inoculation were euthanized.

Cell proliferation {#s4-5}
------------------

Cells were seeded in 96-well plates (1,000 cells/well) and cultured in an IncuCyte Zoom (Essen Bioscience). The cells were kept in growth media and fed every 2 days for the duration of the assay. Images were taken every 4 hr and cell confluence was measured at these time points.

Soft agar growth {#s4-6}
----------------

Agarose (Lonza, Basel, CH) was dissolved in water (4 or 2% (w/v) solution) and autoclaved. The 4% agarose was mixed with growth media to yield a 1% agarose solution, which was plated and allowed to solidify (4°C). Tumor cells in growth media (100,000/6 cm dish) were mixed with the 2% agarose to a final concentration of 0.5% agarose, and overlayed onto the solidified 1% agarose. The cells were fed with Growth Medium every 3 \~ 4 days for the duration of the assay. After 3 weeks, the cells were fixed with 100% methanol (−20°C) and stained with 0.1% crystal violet dissolved in 20% methanol/80% PBS. Images were taken using a Zeiss AxioVert 200M microscope. Six 10x-fields/plate were used to quantify colony formation (≥3000 pixels^2^) using FIJI software ([@bib54]).

Mammosphere assay {#s4-7}
-----------------

Tumor cells were seeded 25,000/ml in a 24-well ultra-low attachment plate in DMEM/F12 media containing 1% penicillin/streptomycin, B27 supplement (1:50), 20 ng/ml bFGF, 2.5 µg/ml insulin, and 20 ng/ml EGF. Six wells were plated for each cell line. Three to four days later, before passaging, colonies larger than 50 µm were counted using a Zeiss AxioVert 200M microscope. The spheres were dissociated by incubation (15 min) with 0.25% trypsin (Thermo Fisher Scientific) with pipetting. The digestion was terminated by addition of 0.5% soybean trypsin inhibitor (ATCC) and single cells were plated. Spheres used for embedding in agarose or for RNA isolation were treated similarly, but were cultured in 100 mm ultra-low attachment dishes. Spheres prepared for embedding were resuspended in 4% agarose (IBI Scientific Cat\# IB70050) and fixed in 10% formalin before processing.

Anoikis assay {#s4-8}
-------------

Tumor cells were suspended in serum-free DMEM/F12 media with 0.5% methylcellulose (Millipore-Sigma), placed in poly-HEMA (Millipore-Sigma) coated plates (1.2 × 10^5^ cells/ml), and incubated for 24 hr. After incubation, the cells were washed twice with PBS, then stained with phycoerythrin-conjugated Annexin V and 7-aminoactinomycin D (7-AAD) using the PE annexin apoptosis detection kit I (BD Pharmingen \#559763). A FACSCalibur (BD Bioscience) was used to quantify the apoptotic cells (7AAD^-^ Annexin V^+^). Single-stained controls were used to gate 7AAD^-^ and 7AAD^+^ cells while cells suspended for 1 hr were used to define the annexin V^+^ and annexin V^-^ populations. FlowJo version 9.7.6 (Tree Star) was used to analyze the data ([@bib21]).

Wound healing {#s4-9}
-------------

Tumor cells were seeded at a density of 100,000 cells/well in a 96-well ImageLock plate (Essen Bioscience) and allowed to adhere overnight. The following day, a Wound Maker (Essen Bioscience) was used to scratch the confluent monolayers of cells. The cells were washed two times with PBS and then maintained in serum-free media for the remainder of the assay. Invasion assays were performed using cells plated in 96-well ImageLock plates coated with 300 µg/ml collagen I. Cells adhered overnight, were scratched using a WoundMaker, and washed twice with media before being placed on ice (5 min). The cells were then overlayed with growth media containing collagen I (0.5 mg/ml). The cells were incubated (30 min at 37°C) to solidify the collagen prior to the addition of DMEM/F12 supplemented with 2% FBS. All plates were imaged every 4 hr using an IncuCyte Zoom (Essen Bioscience).

Transwell migration {#s4-10}
-------------------

Tumor cells (30,000 cells/well) were plated in triplicate using Growth Medium in transwells with 8 µm pores (Millipore Sigma) and allowed to adhere. For invasion assays, inserts coated with Matrigel (Millipore Sigma) were rehydrated according to the manufacturer's instructions before plating cells. To create a serum gradient, media from the upper chambers was replaced with serum-free media. Cells were allowed to migrate for 16--20 hr. Remaining cells in the upper chambers were removed with a cotton swab, then the inserts were fixed with 100% methanol (20 min, −20°C), washed three times with PBS, and stained with 2-(4-amidinophenyl)−1 hr -indole-6-carboxamidine (DAPI). The insert membranes were removed with a scalpel and mounted on a slide for examination using a Zeiss Axiovert 200M microscope. Two to three images at 10x magnification were taken for each membrane. FIJI was used to quantify the migrating cells ([@bib54]).

Histological analysis {#s4-11}
---------------------

Mammary glands \#2--5 were harvested, fixed in 10% formalin, dehydrated, and embedded in paraffin. Hematoxylin and eosin-stained sections (5 µm) were reviewed by a board-certified veterinary pathologist to identify and classify proliferative lesions ([@bib8]). To detect proliferation, sections were treated with the endogenous biotin blocking kit (Thermo Fisher Scientific E21390), prior to incubation with a biotin-conjugated antibody to PCNA (Thermo Fisher Scientific Cat\# 13--3940 RRID:[AB_2533017](https://scicrunch.org/resolver/AB_2533017); dilution 1:50), and an AlexaFluor 633-conjugated streptavidin (Thermo Fisher Scientific Cat\# S-21375 RRID:[AB_2313500](https://scicrunch.org/resolver/AB_2313500)). For PCNA quantification 49--50 fields were examined across JNK^WT^ (n = 4) and JNK^KO^ (n = 5) mice. PCNA positive duct cells were normalized to the total number of duct cells in the field examined. Additional sections were stained with cleaved-caspase-3 (Cell Signaling Technology Cat\# 9662 RRID:[AB_331439](https://scicrunch.org/resolver/AB_331439); 1:100), cytokeratin 5 (BioLegend Cat\# 905501 RRID:[AB_2565050](https://scicrunch.org/resolver/AB_2565050); 1:50), cytokeratin 8 (DSHB Cat\# TROMA-I RRID:[AB_531826](https://scicrunch.org/resolver/AB_531826); 1:100), GFP (Thermo Fisher Scientific Cat\# A21311 RRID:[AB_221477](https://scicrunch.org/resolver/AB_221477); 1:100), estrogen receptor (Santa Cruz Biotechnology Cat\# sc-542 RRID:[AB_631470](https://scicrunch.org/resolver/AB_631470); 1:500), and progesterone receptor (Santa Cruz Biotechnology Cat\# sc-538 RRID:[AB_632263](https://scicrunch.org/resolver/AB_632263); 1:300). For immunohistochemistry, a biotinylated rabbit antibody (Biogenex Cat\# HK340-5K) in conjunction with streptavidin-conjugated horseradish peroxidase (Vector Laboratories Cat\# PK-6100) and 3,3'-diaminobenzidene (Vector Laboratories Cat\# SK-4100) was used to detect the primary antibody. Sections were then counterstained with hematoxylin (Fisher Scientific) and pictures were taken using a Zeiss Axiovert. AlexaFluor 546 conjugated-goat anti-rabbit IgG (H + L) antibody (Thermo Fisher Scientific Cat\# A11035 RRID:[AB_143051](https://scicrunch.org/resolver/AB_143051)) and AlexaFluor 488 conjugated-goat anti-rat IgG (H + L) antibody (Thermo Fisher Scientific Cat\# A11006 RRID:[AB_141373](https://scicrunch.org/resolver/AB_141373)) were used to detect immune complexes in co-staining experiments. These sections were counterstained with DAPI and immunofluorescence was examined using a Leica SP2 confocal microscope.

Immunoblot analysis {#s4-12}
-------------------

Cell lysates were prepared using Triton lysis buffer (20 mM Tris \[pH 7.4\], 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 10 μg/mL of aprotinin and leupeptin). Extracts (30 µg) were examined by immunoblot analysis by probing with antibodies to phospho-ERK (Cell Signaling Technology Cat\# 9101 RRID:[AB_331646](https://scicrunch.org/resolver/AB_331646)), ERK2 (Santa Cruz Biotechnology Cat\# sc-1647 RRID:[AB_627547](https://scicrunch.org/resolver/AB_627547)), phospho-JNK (Cell Signaling Technology Cat\# 9255 RRID:[AB_2307321](https://scicrunch.org/resolver/AB_2307321)), JNK (R and D Systems Cat\# AF1387 RRID:[AB_2140743](https://scicrunch.org/resolver/AB_2140743)), p38 (Cell Signaling Technology Cat\# 9212 RRID:[AB_330713](https://scicrunch.org/resolver/AB_330713)), phospho-p38 (Cell Signaling Technology Cat\# 9211 also 9211L, 9211S RRID:[AB_331641](https://scicrunch.org/resolver/AB_331641)), phospho-JUN (S63) (Cell Signaling Technology Cat\# 9261L RRID:[AB_2130159](https://scicrunch.org/resolver/AB_2130159)), JUN (Santa Cruz Biotechnology Cat\# sc-1694 RRID:[AB_631263](https://scicrunch.org/resolver/AB_631263)), p-AKT (T308) (Cell Signaling Technology Cat\# 5106S RRID:[AB_836861](https://scicrunch.org/resolver/AB_836861)), p-AKT (S473) (Cell Signaling Technology Cat\# 9271 RRID:[AB_329825](https://scicrunch.org/resolver/AB_329825)), AKT (Cell Signaling Technology Cat\# 9272 RRID:[AB_329827](https://scicrunch.org/resolver/AB_329827)), and α-Tubulin (Millipore-Sigma Cat\# T5168 RRID:[AB_477579](https://scicrunch.org/resolver/AB_477579)). IRDye 680LT conjugated-donkey anti-mouse IgG antibody (LI-COR Biosciences Cat\# 926--68022 RRID:[AB_10715072](https://scicrunch.org/resolver/AB_10715072)) and IRDye 800CW conjugated-goat anti-rabbit IgG (LI-COR Biosciences Cat\# 926--32211 RRID:[AB_621843](https://scicrunch.org/resolver/AB_621843)) were used to detect and quantitate immune complexes with the Odyssey infrared imaging system (LI-COR Biosciences).

Exome sequencing {#s4-13}
----------------

Genomic DNA was isolated from cancer cell lines using the DNEasy kit, including RNase treatment (Qiagen). For each genotype, a control sample was generated by isolating genomic DNA from mammary glands of a virgin mouse of the same genotype. Whole exome sequencing libraries were prepared using the Agilent SureSelect XT library preparation kit. DNA (OD260/280 1.7--2.0 and OD260/230 \> 2.0) was sheared using a Covaris LE220. End-repaired, adenylated DNA fragments were ligated to Illumina sequencing adapters and amplified by PCR. Exome capture was performed using the Agilent SureSelect Mouse All Exon (50 mb) capture probe set; captured exome libraries were enriched by PCR. Final libraries were quantified using the KAPA Library Quantification Kit (KAPA Biosystems), Qubit Fluorometer (Life Technologies) and Agilent 2100 BioAnalyzer, and were sequenced on an Illumina HiSeq2500 machine using 2 × 125 bp cycles. Single nucleotide variants were reported as the union of SNVs called by muTect ([@bib13]), Strelka ([@bib53]), and LoFreq ([@bib75]) and indels were reported as the union of indels called by Strelka, somatic versions of Pindel ([@bib77]) and Scalpel ([@bib43]). ExomeCNV was run with default settings using mm10 reference to generate copy-number calls ([@bib52]). The segmentation and log~2~ ratios from ExomeCNV output were used to identify amplified, deleted and copy-neutral regions. Log~2~ thresholds of \>0.2 and \<−0.2 were used to label a segment as amplified or deleted, respectively, and the segments were visualized ([@bib32]). Bedtools ([@bib49]) was run to identify genes overlapping copy-number segments.

Analysis of mRNA expression {#s4-14}
---------------------------

Cellular RNA was isolated using the RNeasy kit with DNase treatment (Qiagen) and RNA quality (RIN \>9) was confirmed using the Bioanalyzer 2100 system (Agilent Technologies). Libraries were constructed according to the manufacturer's instructions (Illumina). Two to three libraries were analyzed for each condition. Single-end sequencing with reads of 40 bp reads (for JNK^WT^ and JNK^KO^) was performed on an Illumina HiSeq 2000 platform and paired-end sequencing with 150 bp reads (for MEC and ME^KO^) was performed on an Illumina NextSeq500 platform ([Figure 2](#fig2){ref-type="fig"}). Poor quality reads, adapter sequences, and reads less than 40 bp were removed using Trimmomatic (version 0.36) ([@bib5]). First, the MEC and ME^KO^ biological groups were analyzed ([Figure 2](#fig2){ref-type="fig"}). Second, to adequately compare the four biological groups (MEC, ME^KO^, JNK^WT^, and JNK^KO^), seqtk was used to sample sequences averaging 40 million single-end reads per sample ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) ([@bib37]). Reads were aligned to the mouse genome mm10 using Bowtie2 (v 2--2.1.0) ([@bib34]) and Tophat2 (v 2.0.14) ([@bib31]). Samtools (version 0.0.19) ([@bib36]) and IGV (version 2.3.60) ([@bib61]) were used for indexing the alignment files and viewing the aligned reads respectively. Cufflinks (v 2.2.1) ([@bib64]; [@bib65]) was used to quantitate gene expression as fragments per kilobase of exon model per million mapped fragments (FPKM); differential expression was identified using the Cufflinks tools, Cuffmerge and Cuffdiff. Cummerbund version 2.4.1 ([@bib64]) was used to assess replicate concordance. The complex heatmap package version 1.12.0 ([@bib23]) was used to generate heatmaps of differentially expressed (q \< 0.05, \|log~2~ Fold Change\| \> 0.75) genes.

Pathway over-representation analysis was performed on differentially expressed genes using the WEB-based GEne SeT AnaLysis Toolkit (Webgestalt) ([@bib70]) with the KEGG database. This analysis was also performed with gene set enrichment analysis (GSEA) software (version 3.0) ([@bib59]) using ranked genes (sign of the log~2~ fold change times the log~10~ *p*-value) ([@bib47]) and the MSigDB gene sets: HALLMARK_KRAS_SIGNALING_UP (M5953); and HALLMARK_DNA_REPAIR (M5898). The gene symbols for the mouse equivalents were used in the gene set enrichment analysis using Ensembl BioMart v87 ([@bib57]).

Ingenuity Pathway Analysis (Qiagen) was used to predict pathway activation based on differentially expressed genes. The top 100 pathways ranked by score (the sum across tumor genotypes of -log~10~ p-value calculated by Fisher's exact test) were identified. Treeview (Java) ([@bib50]) was used to make heatmaps showing pathway activation z-scores.

The expression of mRNA was also determined by RT-PCR using a Quantstudio 12K Flex machine (Thermo Fisher Scientific). TaqMan assays were used to quantify the expression of *Bmi1* (Mm03053308_g1), *Pou5f1* (Mm03053917_g1), and *Nanog* (Mm02019550_s1). Relative expression was normalized to the expression of *18S* RNA in each sample using Taqman assays (catalog number 4308329; Thermo Fisher Scientific).

Statistical analysis {#s4-15}
--------------------

Data are presented as the mean and standard error. Statistical analysis was performed using GraphPad Prism version 7 (GraphPad Software). ANOVA with Bonferroni's test was used to determine significance with an assumed confidence interval of 95%. Two-tailed, unpaired t-test with Welch's correction was used for pairwise comparisons. Fisher's Exact Test was used to determine differences in tumor or MIN incidence. Kaplan-Meier analysis of mammary tumor-free survival was performed using the log-rank test. Statistical significance was defined as p\<0.05.

Data availability {#s4-16}
-----------------

Raw data are presented in the Source Data file. Flow cytometry data have been deposited with FlowRepository (Repository ID:FR-FCM-ZYEV). The RNA-seq data have been deposited with NCBI; GEO accession numbers GSE100581 and GSE92560. The exome sequence data were deposited with NCBI; SRA accession number SRP117075.
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Reviewing Editor
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The cJUN NH~2~-terminal kinase (*JNK*) signaling pathway promotes genome stability and prevents tumor initiation\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jonathan Cooper as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Your paper has been seen by three reviewers, and myself, and we are very happy to consider publication after some revisions that potentially include some new data, some points of clarification/further discussion, and some addressing of minor points. Overall, all three reviewers consider the work presented to be novel and interesting, adding significantly to the existing literature on the role of *JNK* in tumorigenesis, and the context dependency of that. There are some suggested additional data that would enhance mechanistic advance if these can be added, and quite a few points of clarification or discussion that the reviewers felt would be important and/or add to the paper. Some of these were considered important to avoid slightly superficial interpretation of some data in places, particularly around what the model used here was actually reporting. These points are outlined below. We look forward to seeing a revised version.

*Major points:*

1\) The authors cannot use the wording that *JNK* deletion is \'sufficient\' to cause tumors? Only 10 of 32 ME-ko mice had tumors. For Figure 1C the authors need to be explicit in the ages of the mice under observation. What is the latency period of the tumors and MIN lesions? How long were control animals followed? It is surprising the authors have chosen JNKf/f (Cre-negative) animals as their control. Was any *WAP-Cre;JNK*-wt cohort aged during the study?

2\) The main conclusion is that *JNK* suppresses breast cancer initiation; however the authors have recently published that *JNK* deletion results in a delay in mammary gland involution (Girnius et al., CDD). Therefore, could the lesions observed in Figure 7 be due to a lack of clearance post-weaning? This could lead to an expanded pool of cells susceptible to transformation and so a quirk of the *WAP-Cre* model. Have the authors considered using an alternative mammary-specific Cre driver such as *K8-Cre* or *MMTV-Cre* which would obviate the need to induce lactation? At the very least, this should be discussed in more detail. Can *JNK* be deleted in established tumors, either using an inhibitor or perhaps by way of an inducible knockdown orthotopic model?

3\) There are 3 examples of ME-KO tumours in Figure 1D but the authors need to say if these are adenocarcinoma or adenosquamous carcinoma. Ideally at least two examples of each tumor type should be shown. It is not clear if the adenosquamous carcinomas originate in a *JNK*-deleted cell type since the *WAP-cre* driver is CK8-specific (Figure 1A) yet the adenosquamous lesions are predominately CK5 positive. Furthermore, there is no evidence for the trans-differentiation unless the authors can show these CK5+ tumours are *JNK*-deleted.

4\) The RNAseq data presented in Figure 2 demonstrates an upregulation of WNT target genes in ME^KO^ cells, leading the authors to suggest that ME^KO^ tumors could exploit WNT signalling to drive proliferation. Validating this observation at the protein level through IHC of tumor tissue or Western blotting of ME^WT^ and ME^KO^ cell lines would add confidence to this proposed mechanism. Are WNT pathway components differentially expressed between *JNK*^WT^ and *JNK*^KO^ tumor cells in the p53mut background? Based on data in Figure 2E and 2F, would authors predict that *JNK*^KO^ tumor cells should be more sensitive to WNT pathway inhibitors? Has this been tested?

5\) The detection of genomic instability indicators in ME^KO^ tumor cell lines is interesting but perhaps expected when comparing tumor cells with normal epithelial cells. It would have been useful to compare ME^KO^ with ME^WT^ tumor cell lines. It does looks like in the p53mut background, *JNK*^KO^ cells have less SNVs and indels than *JNK*^WT^ cells (Figure 1---figure supplement 2A). Authors should comment on this.

6\) Do gene expression changes associated with *JNK* deficiency in mammary tumor cells correlate with previously published gene signatures associated with genomic instability or DNA damage?

*Points for clarification/discussion:*

7\) Human breast cancers retain expression of JNK1 and JNK2 but exhibit inactivating mutations in upstream components, which will strongly impair activation of *JNK*. This is obviously not the same as the complete ablation of *JNK* expression that the authors employ in this model. Whilst the data presented are strong and provide important new insights into the role of *JNK* in this murine model, the authors do need to explicitly acknowledge and comment on this limitation of their model.

8\) At several places in the manuscript (Introduction and Conclusion) the authors state that their discovery that loss of JNK1/2 expression promotes breast cancer may \'present an opportunity for therapeutic intervention\'. It is not immediately obvious how a small molecule could rescue the effects of losing JNK1/2 expression to prevent genome instability. Presumably they are thinking about a disease stratification approach in which those breast cancers with loss of function mutations on the *JNK* pathway and enhanced genome stability may be more susceptible to intervention with drugs targeting DNA Damage Response (DDR) pathways, analogous to synthetic lethality that has helped to drive approval of PARPi? Or do they envisage combination of JNKi and DDRi as being synthetic lethal in cells that do not have *JNK* pathway mutations? A little more information here, or discussion, would help to clarify ideas and potential significance for the reader.

9\) In Figure 3 and Figure 3---figure supplement 2 the authors describe how the *[Kras]{.ul}* locus is more frequently amplified in JNK^WT^ mice compared to JNK^KO^. Could the authors comment on the significance of this observation? Are they proposing that because the JNK^KO^ tumours display increased genome instability they are likely to acquire many more oncogenic events and thus become less reliant on the amplification of the *Kras* locus which is prevalent in the JNK^WT^ mice?

10.7554/eLife.36389.044

Author response

Major points:

> 1\) The authors cannot use the wording that JNK deletion is \'sufficient\' to cause tumors? Only 10 of 32 ME-ko mice had tumors. For Figure 1C the authors need to be explicit in the ages of the mice under observation. What is the latency period of the tumors and MIN lesions? How long were control animals followed? It is surprising the authors have chosen JNKf/f (Cre-negative) animals as their control. Was any WAP-Cre;JNK-wt cohort aged during the study?

a\) We agree -- we were wrong to state that *JNK*-deficiency is sufficient for tumor formation since tumors were not found in all *JNK*-deficient mice. We have corrected the text to fix this error.

b\) The source data file for Figure 1C provides detailed information concerning the tumors and MIN lesions, including the age of the mice.

c\) We examined tumors in Cre^+^ Control mice (*Cre^+^ Jnk1^+/+^ Jnk2^+/+^*) and Flox Control mice (*Cre^-^ Jnk1^LoxP/LoxP^ Jnk1^LoxP/LoxP^*) as well as experimental *JNK*-deficient mice (*Cre^+^ Jnk1^LoxP/LoxP^ Jnk1^LoxP/LoxP^*). All of these data are presented in the source data file. The Flox Control (*Cre^-^ Jnk1^LoxP/LoxP^ Jnk1^LoxP/LoxP^*) and experimental *JNK*-deficient mice (*Cre^+^ Jnk1^LoxP/LoxP^ Jnk1^LoxP/LoxP^*) are litter-mates, while the Cre^+^ Control mice were obtained from separate litters. For this reason, we present data using littermate control mice (*Cre^-^ Jnk1^LoxP/LoxP^ Jnk1^LoxP/LoxP^*) and experimental JNKdeficient mice (*Cre^+^ Jnk1^LoxP/LoxP^ Jnk1^LoxP/LoxP^*) in the Figure. Nevertheless, data from both Control strains and the experimental strain are presented in the source data file. No breast tumors were detected in the 22 Cre^+^ Control mice (*Cre^+^ Jnk1^+/+^ Jnk2^+/+^*) that were examined.

> 2\) The main conclusion is that JNK suppresses breast cancer initiation; however the authors have recently published that JNK deletion results in a delay in mammary gland involution (Girnius et al., CDD). Therefore, could the lesions observed in Figure 7 be due to a lack of clearance post-weaning? This could lead to an expanded pool of cells susceptible to transformation and so a quirk of the WAP-Cre model. Have the authors considered using an alternative mammary-specific Cre driver such as K8-Cre or MMTV-Cre which would obviate the need to induce lactation? At the very least, this should be discussed in more detail. Can JNK be deleted in established tumors, either using an inhibitor or perhaps by way of an inducible knockdown orthotopic model?

We have revised the paper to cite our paper on the role of *JNK* in involution. We demonstrated that *JNK*-deficiency causes a delay in involution. However, at 14 days post-weaning, we found no differences in breast morphology between control and *JNK*-deficient mice. It is therefore not clear that suppressed involution contributes to the tumor phenotype of *JNK*-deficient mice. However, we have revised the Discussion to discuss this possibility. We did consider the use of *K8-Cre* and *MMTV-Cre* for these studies. However, the expression of *Cre* in these mouse lines is not restricted to the mammary epithelium. The use of these mice is therefore compromised by the ablation of *Jnk* genes in non-mammary tissues. The *WAP-Cre* model causes gene ablation that is restricted to the mammary epithelium.

> 3\) There are 3 examples of ME-KO tumours in Figure 1D but the authors need to say if these are adenocarcinoma or adenosquamous carcinoma. Ideally at least two examples of each tumor type should be shown. It is not clear if the adenosquamous carcinomas originate in a JNK-deleted cell type since the WAP-cre driver is CK8-specific (Figure 1A) yet the adenosquamous lesions are predominately CK5 positive. Furthermore, there is no evidence for the trans-differentiation unless the authors can show these CK5+ tumours are JNK-deleted.

The three ME^KO^ tumors in Figure 1D are representative and include one adenocarcinoma, one adenosquamous carcinoma, and one mixed tumor with characteristics of both adenocarcinoma and adenosquamous carcinoma. We have revised the figure legend to make this clear. No *JNK* was detected by immunoblot analysis in the tumor cells isolated from the *JNK*-deficient mice.

We note that immunoblot analysis demonstrated no *JNK* expression in the adenosquamous carcinoma of *WAPCre^+^ Jnk1^LoxP/LoxP^ Jnk1^LoxP/LoxP^* mice (Figure 1D). This observation suggests that CK5+ adenosquamous carcinoma cells may arise by trans-differentiation of CK8 cells that express Cre, although we acknowledge that this conclusion is speculative. We acknowledge the speculative nature of this conclusion in the subsection "Disruption of JNK signaling causes breast cancer development".

> 4\) The RNAseq data presented in Figure 2 demonstrates an upregulation of WNT target genes in ME^KO^ cells, leading the authors to suggest that ME^KO^ tumors could exploit WNT signalling to drive proliferation. Validating this observation at the protein level through IHC of tumor tissue or Western blotting of ME^WT^ and ME^KO^ cell lines would add confidence to this proposed mechanism. Are WNT pathway components differentially expressed between JNK^WT^ and JNK^KO^ tumor cells in the p53mut background? Based on data in Figure 2E and 2F, would authors predict that JNK^KO^ tumor cells should be more sensitive to WNT pathway inhibitors? Has this been tested?

Our conclusions concerning the role of WNT signaling are based on the data presented in Figure 2 showing increased expression of *Wnt7b* and *Wnt10a* and increased expression of the WNT target genes *Axin2, Myc* and *Ccnd1*. This conclusion is based on gene expression analysis.

The reviewer requests that we provide protein-based evidence for WNT signaling in the tumor cells. A major signaling axis that mediates WNT function is the stabilization and nuclear accumulation of β-catenin that serves to increase WMT target gene expression. We therefore examined the nuclear accumulation of β-catenin by immunofluorescence analysis. Figure A shows accumulation of β-catenin in the nucleus of JNK-deficient tumor cells. This observation is fully consistent with our data showing that tumor cells from *JNK* knockout mice exhibit increased expression of WNT target genes.

We tested the role of autocrine Wnt signaling in the cultured tumour cells by examining the effect of the addition of the WNT antagonist DICKKOPF (R&D Systems) to the culture medium. We found that DICKKOPF caused no change in tumor cell proliferation. We omitted these data from the study for two reasons. First, it is not clear that the rate of proliferation is the most important in vitro property of tumour cells. Second, it is not clear that WNT inhibition by DICKKOPFin vitro mimics the effect of WNT signaling inhibition during tumor development in vivo. We believe that substantially more work is required to establish the role of WNT signaling in the observed tumor development and that this is beyond the scope of the current study.

![Mammospheres prepared from Control (left panel) and *JNK*-deficient (right panel) tumor cells were embedded in paraffin, sectioned, and stained with DAPI and an antibody to β-catenin.\
We found that β-catenin was restricted to the cytoplasm of Control tumor cells, but β-catenin was detected in both the nucleus and cytoplasm of *JNK*-deficient tumor cells.](elife-36389-resp-fig1){#respfig1}

> 5\) The detection of genomic instability indicators in ME^KO^ tumor cell lines is interesting but perhaps expected when comparing tumor cells with normal epithelial cells. It would have been useful to compare ME^KO^ with ME^WT^ tumor cell lines. It does looks like in the p53mut background, JNK^KO^ cells have less SNVs and indels than JNK^WT^ cells (Figure 1---figure supplement 2A). Authors should comment on this.

While the number of SNV and indels caused by TRP53 deficiency was greater than that caused by *JNK* deficiency, the number of CNV were similar on both genetic backgrounds. These observations indicate that while both TRP53deficiency and *JNK*-deficiency cause genomic instability, the mechanisms of genomic instability caused by these two pathways is different. We have added additional discussion of this point to the text.

> 6\) Do gene expression changes associated with JNK deficiency in mammary tumor cells correlate with previously published gene signatures associated with genomic instability or DNA damage?

Gene set enrichment analysis demonstrates decreased expression of a "DNA Repair" gene signature by *JNK* deficient tumor cells (Figure 2---figure supplement 1). These data are included in the revised manuscript.

Points for clarification/discussion:

> 7\) Human breast cancers retain expression of JNK1 and JNK2 but exhibit inactivating mutations in upstream components, which will strongly impair activation of JNK. This is obviously not the same as the complete ablation of JNK expression that the authors employ in this model. Whilst the data presented are strong and provide important new insights into the role of JNK in this murine model, the authors do need to explicitly acknowledge and comment on this limitation of their model.

We agree -- a clear goal for future studies will be to directly test the role of MEKK1 and MAP2K4 *loss-of-function* mutations in breast cancer. We have revised the Discussion to state this important point.

> 8\) At several places in the manuscript (Introduction and Conclusion) the authors state that their discovery that loss of JNK1/2 expression promotes breast cancer may \'present an opportunity for therapeutic intervention\'. It is not immediately obvious how a small molecule could rescue the effects of losing JNK1/2 expression to prevent genome instability. Presumably they are thinking about a disease stratification approach in which those breast cancers with loss of function mutations on the JNK pathway and enhanced genome stability may be more susceptible to intervention with drugs targeting DNA Damage Response (DDR) pathways, analogous to synthetic lethality that has helped to drive approval of PARPi? Or do they envisage combination of JNKi and DDRi as being synthetic lethal in cells that do not have JNK pathway mutations? A little more information here, or discussion, would help to clarify ideas and potential significance for the reader.

We agree that the conclusions on this point were not stated clearly in the original version of our manuscript. Our expectation is that *JNK*-deficiency would exhibit synthetic lethality with drugs that cause DNA damage or prevent DNA repair. We have revised the Discussion to state this more clearly.

> 9\) In Figure 3 and Figure 3---figure supplement 2 the authors describe how the [Kras]{.ul} locus is more frequently amplified in JNK^WT^ mice compared to JNK^KO^. Could the authors comment on the significance of this observation? Are they proposing that because the JNK^KO^ tumours display increased genome instability they are likely to acquire many more oncogenic events and thus become less reliant on the amplification of the Kras locus which is prevalent in the JNK^WT^ mice?

We agree that our conclusions were not clearly stated in the original manuscript. As stated by the reviewers, we suspect that the *Kras* amplification detected in WT tumors was functionally substituted by the mutation of other oncogenic pathways in the *JNK* knockout tumors. We have revised the last paragraph of the subsection "JNK deficiency rapidly accelerates tumor development in a mouse model of breast cancer" to state this more clearly and by including gene set enrichment analysis for a *Kras* signaling signature (Figure 3---figure supplement 3).
